Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Pre-anesthetic dosing of midazolam is commonly used in many hospitals for the induction of anesthesia, but the effect is still controversial. The purpose of this study was to evaluate the effectiveness of midazolam premedication in four aspects: anxiety reduction, pain relief, sedation and hemodynamic stability.
Background
Methods
Subjects
Anesthetic management
Assessment of response to midazolam
Sample size and statistical analysis
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Midazolam premedication group (Group P) | Active Comparator | Patients of group P were premedicated with intramuscular midazolam 0.05 mg/kg 30 minutes before surgery. |
|
| Control group (Group N) | Other | Patients of group N were not premedicated with midazolam (Do not use placebo). [Treatment of Glycopyrrolate (0.2 mg, IM) 30 minutes prior to surgery is not intervention because it is a routine practice of this center. (-> removed from interventions)] |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Midazolam premedication | Drug | Patients in Group P received midazolam (0.05 mg/kg, intramuscular injection) 30 minutes before induction of general anesthesia. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in degree of anxiety | Patients completed the Beck anxiety inventory (BAI) on two separate occasions, the anesthesiologist's visit on the day before surgery and pre-induction time after randomization. The BAI was a self-report questionnaire consisting of 21 questions. | the anesthesiologist's visit on the day before surgery and pre-induction time after randomization |
| Change in sedation level | Measuring the entropy value (CARESCAPE Monitor B850, GE Healthcare, Milwaukee, WI, USA). | At the time of pre-induction (initial), prior to intubation, intubation, prior to incision, and surgical incision |
| Change in noninvasive blood pressure (hemodynamic parameters 1) | Measuring noninvasive blood pressure (CARESCAPE Monitor B850, GE Healthcare, Milwaukee, WI, USA) | At the time of pre-induction (initial), prior to intubation, intubation, prior to incision, and surgical incision |
| Change in SPI value (Analgesic profile 1) | Measuring SPI (CARESCAPE Monitor B850, GE Healthcare, Milwaukee, WI, USA), which was calculated from the pulse oximetry wave | At the time of pre-induction (initial), prior to intubation, intubation, prior to incision, and surgical incision |
| Numeric rating scale (Analgesic profile 2) | Reviewing numeric rating scale (NRS) : 0 (No pain) ~ 10 (Worst possible pain) | Postoperative period (until transition to oral analgesics, up to 12 hours) |
| Analgesic requirement (Analgesic profile 3) | Reviewing additional medications for pain control |
| Measure | Description | Time Frame |
|---|---|---|
| Procedure time of intubation | Total time taken for intubation was recorded | From the beginning of anesthesia to the completion of intubation |
| Correlation analysis between the SPI values and other parameters (heart rate, blood pressure, and entropy values) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Hyeon-Jeong Lee, PhD | Pusan National University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pusan national university hospital | Busan | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014155 | Transcobalamins |
| D000077208 | Remifentanil |
| D015742 | Propofol |
| ID | Term |
|---|---|
| D012712 | Serum Globulins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Remifentanil infusion | Drug | Target controlled infusion of remifentanil (4ng/ml) was used for induction of anesthesia based on the pharmacological models of Minto. After intubation, remifentanil (2 ng/ml) was infused until incision time. (Both groups) |
|
|
| Propofol infusion | Drug | Target controlled infusion of propofol (4.0 μg/ml) was used for induction of anesthesia based on the pharmacological models of Marsh. After intubation, propofol (3.0μg/ml) was infused until incision time. (Both groups) |
|
|
| Postoperative period (until transition to oral analgesics, up to 12 hours) |
| Change in heart rate (hemodynamic parameters 2) | Measuring heart rate (CARESCAPE Monitor B850, GE Healthcare, Milwaukee, WI, USA) | At the time of pre-induction (initial), prior to intubation, intubation, prior to incision, and surgical incision |
Measuring SPI, noninvasive blood pressure, heart rate, and entropy values (CARESCAPE Monitor B850, GE Healthcare, Milwaukee, WI, USA) |
| At the time of pre-induction (initial), prior to intubation, intubation, prior to incision, and surgical incision |
| D002352 |
| Carrier Proteins |
| D005916 | Globulins |
| D011422 | Propionates |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
| D010880 | Piperidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D010636 | Phenols |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |